Comparing two arsenic trioxide administration methods in APL therapy.
Zhou
Jin
J
Hematology Division, The First Clinical Medical College of Harbin Medical University, Harbin 150001, China. Jinzhouh85@163.com
Meng
Ran
R
Yang
Bao-feng
BF
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D007964:Leukocytosis / Q000139:chemically induced; D010087:Oxides / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide